Abbvie Inc.

Abbott Laboratories Corporation

Genentech, Inc.

The Walter and Eliza Hall Institute of Medical Research

Ligand Pharmaceuticals, Inc.

The Walter and Eliza Institute of Medical Research

The Walter and Eliza Hall Medical Research Institute

Abbvie Bahamas Limited

Abbvie Ireland Unlimited Company

Steven Elmore

Xilu Wang

Andrew J Souers

Aaron R Kunzer

Michael D Wendt

Hong Ding

Milan Bruncko

Zhi-Fu Tao

Cheol-Min Park

Xiaohong Song

Gerard M Sullivan

Le Wang

Lisa A Hasvold

Laura A Hexamer

Gary T Wang

William J McClellan

Andrew M Petros

George A Doherty

Robert A Mantei

Christopher L Lynch

Todd M Hansen

Noah Tu

David J Madar

Guillaume Laurent Lessene

Peter Colman

Peter Edward Czabotar

Keith G Watson

John A Flygare

Chudi Obioma Ndubaku

Jonathan Bayldon Baell

Wayne J Fairbrother

Danette Dudley

Brad E Sleebs

Chinh Thien Bui

Alexander R Shoemaker

Brian John Smith

Chang H Park

Michael J Mitten

Xiahong Song

George Nikolakopoulos

Cheol Min Park

Carl Steven Rye

John K Pratt

Wang Shen

David John Augeri

Tariq Ghayur

Daniel A Dickman

Sheela A Thomas

Stuart J Perper

Lichun Wang

James Patrick Edwards

Todd Kevin Jones

Philip R Kym

Dachun Liu

George S Sheppard

Michael E Kort

Saul H Rosenberg

Keith F McDaniel

Jimmie L Moore

Daryl Richard Sauer

Gary B Gordon

Robert Hubbard

Kurt Deshayes

Michael J Coghlan

Alan X Wang

Li Chun Wang

Chaohong Sun

Aaron K Kunzer

William Mcclellan

Andrew Petros

Lisa Hasvold

Laura Hexamer

Michael Wendt

George Doherty

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-X.

Methods of treatment using selective Bcl-2 inhibitors

Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases

The present invention provides for compounds of formula (I) wherein R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Pyrrole-3-carboxamide bromodomain inhibitors

Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

7-substituted indole Mcl-1 inhibitors

This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins. Specifically, the current invention is directed to treatment with compounds that selectively inhibit the activity of Bcl-2 proteins, with a lesser affinity for inhibiting the activity of other BCL-2 family proteins, including Bcl-x.

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases

BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X, X, X, X, R, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xproteins.

Compounds and methods of use

Growing community of inventors

Northbrook, IL, United States of America

Steven Elmore